PharmSci 360: Tuesday’s program highlights

0

Highlights from the Tuesday, Nov. 6 program include:

9:30 a.m. – 10:30 a.m.

* Capturing, Counting and Identifying CECs: A Potential Diagnostic Marker for Patients with Pulmonary Arterial Hypertension

Clinical Pharmacology, Poster Form 5

11:00 a.m. – 4:30 p.m.

* Philanthropic Activity: Rise Against Hunger

Exhibit Hall A/B, Aisle 200

11:30 a.m. – 12:30 p.m.

* Prevention of Cerebral Ischemia/Reperfusion Injury by Neutrophil-Derived Nanovesicles

Bioanalytics, Poster Forum 3

* Development and Evaluation of Bone-Targeting Nanoparticle (BTN) as a New Treatment of Bacterial Bone Infections

Formulation and Quality, Poster Forum 8

1:30 p.m. – 2:30 p.m.

* Development of a Chitosan-shRNA Nanoplex as a Universal Influenza Therapeutic

Preclinical Development, Poster Forum 1

* Continuous Manufacturing and the Role of Models in Implementing Continuous Manufacturing

Sharmista Chatterjee, FDA

Room 147 AB

* Development of Biologics: Making Affordable High Quality Medicines by Leveraging Technologies and Data Analytics

Vikram Sinha, Ph.D. Assoc. Vice President & Head, Quantitative Pharmacology & Pharmacometrics, Merck, Inc.

Room 146 C

* Development, Current Applications, and Future Utility of the Organ on a Chip Technology

Donald Ingber, M.D., Ph.D., Wyss Institute for Biologically Inspired Engineering at Harvard

Room 150 B

* Lessons Learned from 30+ Years of Attempts to Become a Formulation Scientist

Wim Jiskoot, Ph.D., Professor, Univ. Leiden

Room 146 A

* Mass Spec Technology

Nathan Yates, Ph.D., Associate Professor, Department of Cell Biology and Scientific Director of the Biomedical Mass Spectrometry Center, University of Pittsburgh

Room 151 B

* New and Upcoming Drug Modalities

Ray Deshaies, Ph.D., Senior Vice President, Discovery Research, Amgen, Inc.

Room 150 A

* Non-traditional Approaches to Bioequivalence & Application of Clinical Pharmacology to Minimize Barriers to Generic Drug Substitution

Kathleen Uhl, M.D., Director, Office of Generic Drugs, FDA/Center for Drug Evaluation and Research

Room 152 AB

* State of the Art and Future Perspectives on the Predictive Immunogenicity

Bernard Maillère, Ph.D., CEA

Room 151 A

* Strategies and Visions for Continuous Biologics Manufacturing from End to End

Joseph Shultz, Novartis Pharma AG

Room 145 AB

* Transforming the Patient Experience Through Long Acting Injectable/Implantable Formulations: New Opportunities and Technologies

Matthew Burke, Ph.D., GlaxoSmithKline

Room 146 B

###

About AAPS:

The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific organization of approximately 9,000 members employed in academia, industry, government, and other research institutes worldwide. Founded in 1986, AAPS advances the capacity of pharmaceutical scientists to develop products and therapies that improve global health. Visit http://www.aaps.org and follow us on LinkedIn, Facebook and Twitter @AAPSComms. The official Twitter hashtags for AAPS are: #AAPS2018 and #PharmSci360.

Media Contact

Stacey May
[email protected]
703-459-7677
@AAPSComms

http://www.aaps.org

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.